<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03285750</url>
  </required_header>
  <id_info>
    <org_study_id>GPR120 study</org_study_id>
    <nct_id>NCT03285750</nct_id>
  </id_info>
  <brief_title>Expression of G-protein Coupled Receptor 120 (GPR120) Receptor in Adipose Tissue of German Diabetes Center (GDC) Cohort Subjects</brief_title>
  <acronym>GPR120</acronym>
  <official_title>Expression of GPR120 Receptor in Adipose Tissue of Type 2 Diabetic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German Diabetes Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      G-protein coupled receptor 120 (GPR120) is a G-protein-coupled receptor whose endogenous
      ligands have been identified as long-chain fatty acids. Recently, it has been shown that
      GPR120 expression in human adipose tissue is higher in obese than in lean individuals.
      Interestingly, a GPR120 deficient mouse model presents an unfavorable phenotype when fed a
      high-fat diet with obesity, glucose intolerance and fatty liver, characteristics also found
      in type 2 diabetes (T2D).

      Moreover, in obese subjects, a single nucleotide polymorphism (R270H) has been identified
      that inhibits GPR120 signaling activity.

      The investigators now want to investigate if GPR120 expression in adipose tissue may be
      altered in patients with T2D compared to non-diabetic subjects and might contribute to
      diabetes-associated metabolic changes. Additionally, the investigators want to assess the
      frequency of the R270H mutant in T2D.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>GPR120 expression in adipose tissue</measure>
    <time_frame>Expression measured at baseline (day 1)</time_frame>
    <description>GPR expression is measured in adipose tissue of recently diagnosed type 2 diabetic patients and age- and BMI-matched normoglycemic controls</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Fatty Acid Metabolism and GPR120 Expression in Adipose Tissue</condition>
  <arm_group>
    <arm_group_label>Diabetic group</arm_group_label>
    <description>Patients with recently diagnosed type 2 diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Age- and BMI-matched normoglycemic subjects</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      SNP Genotyping of GPR120
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with recently diagnosed type 2 diabetes (up to one year from diagnosis) and age-
        and weight-matched normoglycemic controls
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus / normoglycemia

          -  BMI &lt; 27,5 or &gt; 30 kg/m2

          -  Age 20 - 69 years

        Exclusion Criteria:

          -  severe chronic diseases

          -  anemia

          -  medication altering fatty acid metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Roden, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Diabetes Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>German Diabetes Center</name>
      <address>
        <city>Duesseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2013</study_first_submitted>
  <study_first_submitted_qc>September 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2017</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>German Diabetes Center</investigator_affiliation>
    <investigator_full_name>julia szendr√∂di</investigator_full_name>
    <investigator_title>PhD Dr. Julia Szendroedi</investigator_title>
  </responsible_party>
  <keyword>GRP120</keyword>
  <keyword>Adipose tissue</keyword>
  <keyword>Type 2 diabetes</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

